Development of Keap1‐Nrf2 Protein–Protein Interaction Inhibitor Activating Intracellular Nrf2 Based on the Naphthalene‐2‐acetamide Scaffold, and its Anti‐Inflammatory Effects
Authors:
Open Access
- 3 September 2025
- journal article
- Published by Wiley in ChemMedChem
- Vol. 20 (21) , e202500474
Abstract
Nuclear factor erythroid 2‐related factor 2 (Nrf2) and Kelch‐like ECH‐associated protein 1 (Keap1) axis is an attractive therapeutic target for various intractable diseases. Although protein–protein interaction inhibitors against Keap1‐Nrf2 have been developed over the past decade, more structural expansion is needed to improve efficacy. In this article, several candidate compounds are designed and synthesized as novel Nrf2 activators and their intracellular Nrf2‐activating effects are evaluated. Among the synthesized compounds, a novel naphthalene‐1,4‐(4‐ethoxybenzensulfonamide) bearing a tertiary acetamide side chain at the 2‐position strongly activated intracellular Nrf2. Particularly, the pyrrolidine‐type acetamide compound showed the strongest intracellular Nrf2 activation. X‐ray cocrystallography revealed that this compound can bind to the DC domain of Keap1. Additionally, the pyrrolidine‐type acetamide compound induced the mRNA expression of the representative Nrf2 target genes heme oxygenase‐1 and NAD(P)H:quinone oxidoreductase 1. Moreover, the compound exhibited anti‐inflammatory effects in a lipopolysaccharide‐stimulated macrophage cell line. Conclusively, these results suggest that the pyrrolidine‐type naphthalene‐2‐acetamide is a promising compound for the development of Nrf2 activators that can be applied to treat inflammatory diseases.Keywords
Funding Information
- Japan Science Society (2023−3028)
This publication has 44 references indexed in Scilit:
- Advances in developing noncovalent small molecules targeting Keap1Drug Discovery Today, 2023
- Optimization of 1,4-bis(arylsulfonamido)naphthalene-N,N'-diacetic acids as inhibitors of Keap1-Nrf2 protein-protein interaction to suppress neuroinflammationBioorganic & Medicinal Chemistry, 2021
- Transcription factor NRF2 as a promising therapeutic target for Alzheimer’s diseaseFree Radical Biology and Medicine, 2020
- Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study)Kidney International Reports, 2020
- Discovery of benzo[g]indoles as a novel class of non-covalent Keap1-Nrf2 protein-protein interaction inhibitorBioorganic & Medicinal Chemistry Letters, 2017
- Synthesis of Keap1-phosphorylated p62 and Keap1-Nrf2 protein-protein interaction inhibitors and their inhibitory activityBioorganic & Medicinal Chemistry Letters, 2016
- Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanismBioorganic & Medicinal Chemistry, 2013
- Discovery of a small-molecule inhibitor and cellular probe of Keap1–Nrf2 protein–protein interactionBioorganic & Medicinal Chemistry Letters, 2013
- A Novel Design of Artificial Membrane for Improving the PAMPA ModelPharmaceutical Research, 2008
- Structural Basis for Defects of Keap1 Activity Provoked by Its Point Mutations in Lung CancerMolecular Cell, 2006